City
Epaper

Amanta Healthcare Limited Files DRHP With SEBI For Fresh Issue of 1.25 Crore Equity Shares

By ANI | Updated: October 4, 2024 15:45 IST

PNNMumbai (Maharashtra) [India], October 4: Amanta Healthcare Limited (Amanta, The Company) engaged in the development, manufacturing, and marketing ...

Open in App

PNN

Mumbai (Maharashtra) [India], October 4: Amanta Healthcare Limited (Amanta, The Company) engaged in the development, manufacturing, and marketing of a diverse range of sterile liquid products, has filed its Draft Red Herring Prospectus with NSE & BSE in preparation for the IPO, The issue size will be of up to 1,25,00,000 equity shares with a face value of Rs 10 each, all of which will be issued as a Fresh Issue.

Amanta's objective is to raise funds for capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up new manufacturing line for SteriPort at Hariyala, Kheda, Gujarat. It also aims to secure funding for capital expenditure requirements towards purchase of equipment, plant and machinery for setting up a new Small Volume Parenteral (SVP) manufacturing line at the same location and general corporate purposes.

For the period ended 31st March 2024, The company reported Revenue of Rs 28,034.03 Lakhs and EBITDA of Rs 5,875.65 Lakhs & PAT of Rs 363.32 Lakhs.

About Amanta Healthcare Limited

Amanta Healthcare Limited is a pharmaceutical company specializing in the development, manufacturing, and marketing of sterile liquid products. Using Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies, Amanta produces parenteral solutions that offer rapid drug absorption for patients who cannot take oral medication.

Amanta manufactures large and small volume parenterals (LVPs and SVPs) across six therapeutic segments, including fluid therapy, ophthalmics, and respiratory care, as well as medical devices. Amanta's facility in Gujarat adheres to global GMP standards, and the company exports its products to 19 countries, with 113 active international product registrations.

In addition to marketing over 45 generics in India through a network of 289 distributors, Amanta partners with pharmaceutical companies to manufacture products at scale. The company is led by a highly experienced management team, committed to innovation and ensuring the highest standards of quality in healthcare.

(ADVERTORIAL DISCLAIMER: The above press release has been provided by PNN.will not be responsible in any way for the content of the same)

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

InternationalPakistan using Turkish drones, China backing it: Rashid Alvi

Other SportsCA closely monitoring Indo-Pak tensions as security concerns grow among players

NationalChandigarh administration issues air warning alert, sounds sirens

NationalPakistan using Turkish drones, China backing it: Rashid Alvi

BusinessDEVI Sansthan's Leadership Circle 3 Sees Over 600 Educators Join Forces for FLN and NIPUN 2027

Business Realted Stories

BusinessNifty, Sensex open lower as geo-political tensions flare up

BusinessIndia, Chile make progress on comprehensive economic partnership agreement

BusinessWith escalation of tension at border, Nifty, Sensex open in negative

BusinessIndia UK FTA paves way for similar agreements with countries like USA, EU: Bank of Baroda

BusinessPromoter holdings in Nifty-500 drop to record low of 49.5% in March 2025; retail holdings remain stable: Motilal Oswal